EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSOMYG00000026946
Gene Symbol: PPP3CA
1 Cross references
228 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSOMYG00000030244
Gene Symbol: PTK2BB
1 Cross references
190 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11a

Ensembl ID : ENSOMYG00000018059
Gene Symbol: PTPN11A
2 Cross references
245 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOMYG00000011020
Gene Symbol: PTPRB
1 Cross references
185 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOMYG00000048747
Gene Symbol: PTPRB
1 Cross references
187 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSOMYG00000022030
Gene Symbol: P2RX3A
1 Cross references
187 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSOMYG00000036882
Gene Symbol: P2RX3A
1 Cross references
186 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSOMYG00000018814
Gene Symbol: P2RX3B
1 Cross references
190 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSOMYG00000005515
Gene Symbol: P2RX3B
1 Cross references
191 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSOMYG00000012263
Gene Symbol: P2RX7
1 Cross references
185 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSOMYG00000041139
Gene Symbol: P2RX7
1 Cross references
185 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSOMYG00000017906
Gene Symbol: P2RY1
2 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).